ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

ClinicalTrials.gov ID: NCT04145349

Public ClinicalTrials.gov record NCT04145349. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 1:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

Study identification

NCT ID
NCT04145349
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
30 participants

Conditions and interventions

Interventions

  • Cyclophosphamide Drug
  • Ramucirumab Drug
  • Vinorelbine Drug

Drug

Eligibility (public fields only)

Age range
12 Months to 29 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 21, 2020
Primary completion
Jun 13, 2024
Completion
Jan 22, 2026
Last update posted
May 10, 2026

2020 – 2026

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
Phoenix Children's Hospital Phoenix Arizona 85016
Children's Hospital of Los Angeles Los Angeles California 90027
Children's National Medical Center Washington D.C. District of Columbia 20010
Washington University St Louis Missouri 63110
Memorial Sloan Kettering Cancer Center New York New York 10065
Children's Hospital of Philadelphia (CHOP) Philadelphia Pennsylvania 19104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04145349, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 10, 2026 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04145349 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →